BDX Faces Monopoly Allegations in U.S. Hernia Mesh Market, Impacting Patient Choices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy BDX?
Source: Benzinga
- Monopoly Allegations: TELA Bio's lawsuit claims that Becton Dickinson controls approximately 65% of the U.S. permanent hernia mesh market and 77% of the resorbable mesh market, leveraging its dominance to raise costs for hospitals and limit patient choices.
- Restrictive Contracts: The complaint alleges that Becton Dickinson used overlapping, multi-year contracts with hospitals and purchasing organizations to restrict access to OviTex, resulting in TELA Bio's marginal market share despite physician preference for its product.
- Patient Impact: The lawsuit highlights a case where a surgeon was denied approval to use OviTex due to Becton Dickinson's contracts, leading to a patient's worsening condition and eventual death during surgery, illustrating the direct harm caused by these practices.
- Legal Consequences: TELA Bio seeks damages and injunctive relief to restore competition and expand choices for patients and providers, while Becton Dickinson faces over 30,000 related lawsuits, indicating escalating legal risks for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 207.390
Low
183.00
Averages
202.38
High
220.00
Current: 207.390
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Becton, Dickinson and Company Stock in Focus
- Intensifying Market Competition: Becton, Dickinson faces fierce competition in the medical device distribution sector, particularly as Boston Scientific's dominance in the pulse field ablation market is challenged, indicating that changing market dynamics could impact the company's performance.
- Investment Potential Assessment: While Becton, Dickinson is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, implying that investors should be cautious in their selections.
- Diverse Medical Supply Portfolio: Becton, Dickinson sells a significant variety of medical supplies, diagnostic tools, and lab equipment, widely used by healthcare professionals and researchers, highlighting its importance and demand in the healthcare industry.
- Market Dynamics Observation: Jim Cramer expresses a bullish view on Becton, Dickinson, suggesting that its performance in the medical device sector is worth monitoring, reflecting investor optimism about the company's future prospects.
See More
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Market Sentiment Improves as Nasdaq Rises Over 200 Points
- Sentiment Recovery: The CNN Money Fear & Greed Index rose to 48.3 on Monday, entering the 'Neutral' zone from a previous reading of 43.9, indicating improved market sentiment that may attract more investors.
- Broad Market Gains: U.S. stocks mostly closed higher on Monday, with the Nasdaq Composite jumping over 200 points to 23,238.67, suggesting strong performance in tech stocks driving overall market positivity.
- Dow Jones Record High: The Dow Jones index increased by about 20 points to 50,135.87 on Monday, marking a new record, reflecting enhanced investor confidence in economic recovery that could further propel market growth.
- Sector Performance Divergence: While most sectors in the S&P 500 closed positively, with materials, energy, and information technology stocks leading gains, consumer staples and healthcare stocks fell, indicating a divergence in market performance that may influence investor decisions.
See More
US Stocks Rise on Monday as Tech Stocks Rebound
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
See More
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
Becton, Dickinson and Company Stock in Focus
- Intensifying Market Competition: Becton, Dickinson faces fierce competition in the medical device distribution sector, particularly as Boston Scientific's dominance in the pulse field ablation market is challenged, indicating that changing market dynamics could impact the company's performance.
- Investment Potential Assessment: While Becton, Dickinson is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, implying that investors should be cautious in their selections.
- Diverse Medical Supply Portfolio: Becton, Dickinson sells a significant variety of medical supplies, diagnostic tools, and lab equipment, widely used by healthcare professionals and researchers, highlighting its importance and demand in the healthcare industry.
- Market Dynamics Observation: Jim Cramer expresses a bullish view on Becton, Dickinson, suggesting that its performance in the medical device sector is worth monitoring, reflecting investor optimism about the company's future prospects.
See More
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Market Sentiment Improves as Nasdaq Rises Over 200 Points
- Sentiment Recovery: The CNN Money Fear & Greed Index rose to 48.3 on Monday, entering the 'Neutral' zone from a previous reading of 43.9, indicating improved market sentiment that may attract more investors.
- Broad Market Gains: U.S. stocks mostly closed higher on Monday, with the Nasdaq Composite jumping over 200 points to 23,238.67, suggesting strong performance in tech stocks driving overall market positivity.
- Dow Jones Record High: The Dow Jones index increased by about 20 points to 50,135.87 on Monday, marking a new record, reflecting enhanced investor confidence in economic recovery that could further propel market growth.
- Sector Performance Divergence: While most sectors in the S&P 500 closed positively, with materials, energy, and information technology stocks leading gains, consumer staples and healthcare stocks fell, indicating a divergence in market performance that may influence investor decisions.
See More
US Stocks Rise on Monday as Tech Stocks Rebound
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
See More
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
